BTG chief nets £18m payout

THE chief executive of former stock market darling BTG has pocketed £18m from its sale to a US pharmaceuticals titan.

Dame Louise Makin was handed the payout after overseeing serious illness specialist BTG’s £3.3bn acquisition by Boston Scientific.

Makin, 58, ran BTG for 14 years as a listed company. The Boston takeover valued shares at 840p each – 37pc more than their value on the stock market at the time.

She picked up the money as her bonus schemes paid out when the deal completed.

BTG was set up in 1948 as the state-owned National Research Development Corporation to help private companies make money from publicly funded research.

It was privatised in 1992 and now focuses on interventional medicine for diseases such as liver cancer.